Sort   by:  
 Page size 
TranscriptomicsX-inactivation in hESCs
X chromosome inactivation (XCI) is a dosage compensation mechanism in female cells to regulate X-linked gene expression. We report here that subcultures from established lines of female hESCs displayed variations (0-100%) in the expression of XCI markers such as XIST RNA coating and enrichment of h...
ORGANISM(S): Homo sapiens 
2010-05-26 | E-GEOD-9637 | biostudies-arrayexpress
GenomicsEvolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined. DNA hypermethylation of the O 6 -methylguanine-DNA methyltransferase (MGMT) promoter is associated with an improve...
EGAS00001001179 | EGA
GenomicsJ_Costello_20140127_dataset - samples
Dataset contains MeDIP-Seq, MRE-Seq and H3K4me3 ChIP-Seq data on 5 GBM patients.
EGAD00001000777 | EGA
GenomicsRecurrent epimutations activate gene body promoters in primary glioblastoma
Aberrant DNA hypomethylation may play an important role in the growth rate of glioblastoma (GBM), but the functional impact on transcription remains poorly understood. We assayed the GBM methylome with MeDIP-seq and MRE-seq, adjusting for copy number differences, in a small set of non-glioma CpG isl...
EGAS00001000685 | EGA
GenomicsJ_Costello_20150506_dataset - samples
Dataset contains Exome-seq and RNA-seq from 2 GBM patients, as well as RNA-seq from the derived cultured cells (GNS).
EGAD00001001359 | EGA
GenomicsThe transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
Reactivation of telomerase reverse transcriptase (TERT) expression enables cells to overcome replicative senescence and escape apoptosis, fundamental steps in the initiation of human cancer. Multiple cancer types, including up to 83% of glioblastomas (GBM), harbor highly recurrent TERT promoter mut...
EGAS00001001242 | EGA
GenomicsMutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Tumor recurrence is a leading cause of cancer mortality. Therapies for recurrent disease may fail, at least in part, because the genomic alterations driving the growth of recurrences are distinct from those in the initial tumor. To explore this hypothesis, we sequenced the exomes of 23 initial low-g...
EGAS00001000579 | EGA
Genomicsena-DATASET-VUMC-CCA-03-09-2014-18:57:30:134-11 - samples
Background: The disease course of patients with diffuse low-grade glioma is notoriously unpredictable. Temporal and spatially distinct samples may provide insight into the evolution of clinically relevant copy number aberrations (CNAs). The purpose of this study is to identify CNAs that are indicati...
EGAD00001001000 | EGA
GenomicsJ_Costello_20150303_dataset - samples
Dataset contains WES data from 3 astrocytoma patients: blood as control, primary tumor and recurrent tumor
EGAD00001001305 | EGA
GenomicsJ_Costello_20130912_dataset - samples
Description not provided
EGAD00001000714 | EGA
Sort   by:  
 Page size